Table 2.
Variable | None anti-diabetic medications
|
Non-metformin anti-diabetic medications
|
Metformin
|
||||
---|---|---|---|---|---|---|---|
OR | OR | 95% CI | P-value | OR | 95%CI | P-value | |
Overall prostate cancer risk | |||||||
No. with cancer/total | 43/205 | 30/141 | 49/194 | ||||
Univariable | Referent | 1.02 | 0.60–1.72 | 0.946 | 1.27 | 0.80–2.03 | 0.311 |
Multivariable* | Referent | 0.85 | 0.48–1.48 | 0.560 | 1.19 | 0.72–1.99 | 0.495 |
| |||||||
Disease grade, low grade# | |||||||
No. with cancer/total** | 33/195 | 20/131 | 31/176 | ||||
Univariable | Referent | 0.88 | 0.48–1.62 | 0.691 | 1.05 | 0.61–1.80 | 0.860 |
Multivariable* | Referent | 0.79 | 0.42–1.49 | 0.463 | 1.01 | 0.57–1.81 | 0.961 |
| |||||||
Disease grade, high grade# | |||||||
No. with cancer/total*** | 10/172 | 10/121 | 18/163 | ||||
Univariable | Referent | 1.46 | 0.59–3.62 | 0.415 | 2.01 | 0.90–4.50 | 0.089 |
Multivariable* | Referent | 1.23 | 0.46–3.26 | 0.678 | 1.83 | 0.75–4.46 | 0.185 |
OR, odds ratio
CI, confidence interval
Adjusted for age, race, geographic region, prostate specific antigen levels, digital rectal examination findings, body mass index, prostate volume, family history of prostate cancer, coronary artery disease, smoking status, NSAIDs, statins, aspirin, and treatment group
Numbers reflect men included in the analysis: those with low-grade disease and those without cancer
Numbers reflect men included in the analysis: those with high-grade disease and those without cancer
Multinomial regression was used to model the outcomes of low vs. no prostate cancer and high grade disease vs. no prostate cancer.